8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 8, 2024)

Filed January 8, 2024For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report announcing preliminary financial results for the fourth quarter and full year 2023. Key takeaways include strong preliminary net product revenues for their key therapies, ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. The company reported approximately $346 million in global net product revenues for Q4 2023 and an impressive $1,241 million for the full year 2023. Furthermore, Alnylam concluded 2023 with a robust cash position, reporting approximately $2.4 billion in cash, cash equivalents, and marketable securities as of December 31, 2023. These preliminary figures provide an early look at the company's performance ahead of their full financial results announcement scheduled for February 2024, indicating positive momentum in revenue generation and a healthy balance sheet.

Key Highlights

  • 1Preliminary Q4 2023 global net product revenues reached approximately $346 million.
  • 2Preliminary full-year 2023 global net product revenues were approximately $1,241 million.
  • 3The reported revenues encompass ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®.
  • 4The company's preliminary cash, cash equivalents, and marketable securities stood at approximately $2.4 billion as of December 31, 2023.
  • 5These results are preliminary and unaudited, subject to adjustment.
  • 6Full financial results are expected to be announced in February 2024.

Frequently Asked Questions

Alnylam announced preliminary global net product revenues of approximately $346 million for the fourth quarter of 2023 and approximately $1,241 million for the full year 2023.

The preliminary revenues reported include sales from ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran).

As of December 31, 2023, Alnylam reported a preliminary cash, cash equivalents, and marketable securities balance of approximately $2.4 billion.

No, these are preliminary and unaudited results, subject to adjustment. The company plans to announce its complete financial results in February 2024.